Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal

Main Article Content

K Gordon
P Foley
JG Krueger
A Pinter
K Reich
R Vender
V Vanvoorden
C Madden
L Peterson
A Blauvelt

Keywords

Psoriasis, Plaque Psoriasis, Biologic, Il-17A, Il-17F, Bimekizumab, Withdrawal, Efficacy, Safety

Abstract

Abstract not available.

References

1. Durham L. Curr Rheumatol Reports 2015;17:55

2. Fujishima S. Arch Dermatol Res 2010;302:499–505

3. Johnston A. et al. J Immunol 2013;190:2252–62

4. Papp K. et al. JAAD 2018;79(2):277–286, NCT02905006

5. Blauvelt A. et al. AAD 2019 (OP11180), NCT03010527

6. Glatt S. et al. Br J Clin Pharm 2017;83(5):991i1001

7. Glatt S. et al. Ann Rheum Dis 2018;77:523–32.